18-months relaps free survival (RSF) and biomarker analyses of OpACIN-neo: a study to identify the optimal dosing schedule of neoadjuvant Ipilimumab (Ipi) + Nivolumab (Nivo) in stage III melanoma - Rozeman, EA; Menzies, AM; Krijgsman, O (Ann Oncol, 2019)
et al.